by GlyTherix | Sep 10, 2020
PRESS RELEASE September 10, 2020 Adelaide, Australia and Sydney, Australia. CAR-T biotherapeutics company Carina Biotech and immuno-oncology company GlyTherix are pleased to announce a co-development agreement that could result in a promising new CAR-T therapy that is...
by GlyTherix | Aug 3, 2020
Recently GlyTherix’s CEO Brad Walsh shared an update on the company with Louise Weihart from Acuris Mergermarket. Briefly, it was said that GlyTherix Ltd is seeking AUD 7M in a Series A equity round, after securing up to AUD 3M in non-dilutive funding from Round 9 of...
by GlyTherix | Jul 16, 2020
16th July 2020: Sydney • Project boasts a dream team of world class partners across antibody manufacturing and clinical trials • Grant will support development of national capability in manufacture and distribution of radioimmuno-oncology drugs • GlyTherix’s...
by GlyTherix | Jun 17, 2020
Explore the impact of the pandemic lockdown on medtech, biotech and pharma sectors in Australia by downloading MTPConnect’s COVID-19 Impact...
by GlyTherix | May 19, 2020
Tuesday 19th May 2020: Sydney GlyTherix Ltd (GlyTherix) is pleased to report publication of four new peer reviewed papers covering both basic science as well as pre-clinical studies around our proprietary novel target, Glypican-1 and our lead antibody to this target,...
by GlyTherix | Sep 19, 2019
GlyTherix is among 25 biotech companies presenting at the AusBiotech Invest & Partnering Session on Thursday 31 October at Melbourne Convention & Exhibition Centre. Brad Walsh will provide an update on Miltuximab, the company’s novel treatment for solid...